scholarly journals Future Aspects of Prostate Biopsy – The Use of Primary Circulating Prostate Cells to Select Patients for Prostate Biopsy: Evidence, Utility and Cost-Benefit

10.5772/28697 ◽  
2011 ◽  
Author(s):  
Nigel P. ◽  
Eduardo Reyes ◽  
Nelson Orellana ◽  
Ricardo Duenas ◽  
Cinthia Fuentealba ◽  
...  
Keyword(s):  
Prostate Biopsy ◽  
Cost Benefit ◽  
Prostate Cells

scholarly journals Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Nigel P. Murray ◽  
Eduardo Reyes ◽  
Leonardo Badínez ◽  
Nelson Orellana ◽  
Cynthia Fuentealba ◽  
...  
Keyword(s):  
Prostate Biopsy ◽  
Healthy Subjects ◽  
Chronic Prostatitis ◽  
Mononuclear Cells ◽  
Benign Disease ◽  
Clinical Implications ◽  
Quantitative Real Time Pcr ◽  
Prostate Cells ◽  
Benign Prostate

Introduction. Developments in immunological and quantitative real-time PCR-based analysis have enabled the detection, enumeration, and characterization of circulating tumor cells (CTCs). It is assumed that the detection of CTCs is associated with cancer, based on the finding that CTCs can be detected in all major cancer and not in healthy subjects or those with benign disease.Methods and Patients. Consecutive men, with suspicion of prostate cancer, had blood samples taken before prostate biopsy; mononuclear cells were obtained using differential gel centrifugation and CPCs detecting using anti-PSA immunocytochemistry. Positive samples underwent further classification with anti-P504S.Results. 329 men underwent prostate biopsy; of these men 83 underwent a second biopsy and 44 a third one. Of those with a biopsy negative for cancer, 19/226 (8.4%) had CPCs PSA (+) P504S (−) detected at first biopsy, 6/74 (8.1%) at second biopsy, and 5/33 (15.2%) at third biopsy. Men with cancer-positive biopsies did not have PSA (+) P504S (−) CPCs detected. These benign cells were associated with chronic prostatitis.Conclusions. Patients with chronic prostatitis may have circulating prostate cells detected in blood, which do not express the enzyme P504S and should be thought of as benign in nature.

scholarly journals A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Nigel P. Murray ◽  
Eduardo Reyes ◽  
Nelson Orellana ◽  
Cynthia Fuentealba ◽  
Ricardo Dueñas
Keyword(s):  
Prostate Biopsy ◽  
Diagnostic Yield ◽  
Screening Tests ◽  
Total Serum ◽  
Low Grade ◽  
Predictive Values ◽  
Psa Density ◽  
Prostate Cells ◽  
Specificity And Sensitivity ◽  
Psa Velocity

Introduction. PSA parameters have been used in an attempt to improve the diagnostic yield of prostate screening tests; the detection of primary malignant circulating prostate cells (CPCs) may improve the diagnostic yield of screening and therefore avoid unnecessary biopsies.Patients and Methods. Prospective study of all men undergoing initial prostate biopsy due to an elevated total serum PSA. Free percent PSA, PSA velocity, and PSA density were determined. Primary CPCs were detected using standard immunocytochemistry. A positive test for CPCs was defined as one cell PSA (+) P504S (+) in an 8 ml blood sample. Positive predictive and negative predictive values, specificity, and sensitivity were calculated for each test as well as the number of biopsies avoided and cancers missed.Results. 303 men participated in the study of whom 113/303 (37.3%) men had prostate cancer. Of the three PSA based parameters, free percent PSA was superior, sensitivity 70.8%, and specificity 67.4%. Primary CPCs detection had a sensitivity of 88.5% and a specificity of 88.4% avoiding 181 (59.7%) biopsies, detecting 93/95 (98%) of clinically significant cancers, and missing 13 (11.5%) low grade, small volume tumors.Conclusions. The use of primary CPCs as a sequential test could decrease the number of initial prostate biopsies missing those cancers which are treated by active observation.

Cost-Benefit and Outcome Analysis: Effect of Prostate Biopsy Undergrading

Urology ◽  
2007 ◽  
Vol 69 (6) ◽  
pp. 1152-1156 ◽  
Author(s):  
Angelo J. Cambio ◽  
Lars M. Ellison ◽  
Karim Chamie ◽  
Ralph W. deVere White ◽  
Christopher P. Evans
Keyword(s):  
Prostate Biopsy ◽  
Cost Benefit ◽  
Outcome Analysis

396: Does a Prostate Biopsy Scheme with a Saturation Technique Improve the Cancer grade, stage and Margin status more Accurately at the Time of Radical Prostatectomy ?

2007 ◽  
Vol 177 (4S) ◽  
pp. 132-132
Author(s):  
Stephane Mallick ◽  
Yann Fouques ◽  
Sophie Le Toquin ◽  
Antoine Dufour ◽  
Henri Bensadoun
Keyword(s):  
Radical Prostatectomy ◽  
Prostate Biopsy ◽  
Margin Status

530: Termining Risk for Prostate Cancer at Prostate Biopsy using Genetic Markers

2005 ◽  
Vol 173 (4S) ◽  
pp. 144-145
Author(s):  
Robert K. Nam ◽  
William Zhang ◽  
John Trachtenberg ◽  
Michael A.S. Jewett ◽  
Steven Narod
Keyword(s):  
Prostate Cancer ◽  
Genetic Markers ◽  
Prostate Biopsy

1497: Predictive Value of Proliferative Inflammatory Atrophy (PIA) for Prostate Cancer on Repeat Prostate Biopsy

2006 ◽  
Vol 175 (4S) ◽  
pp. 483-483
Author(s):  
Charlie Jung ◽  
Michael S. Cookson ◽  
Matthew J. Putzi ◽  
Sam S. Chang ◽  
Joseph A. Smith ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Biopsy ◽  
Predictive Value ◽  
Proliferative Inflammatory Atrophy

1965: Are Quinolones Still Effective Prophylaxis for Prostate Biopsy? the Incidence of Quinolone Resistant Infections after Prostate Biopsy

2007 ◽  
Vol 177 (4S) ◽  
pp. 652-652
Author(s):  
Joseph R. Feliciano ◽  
Paul Carey ◽  
William Blank ◽  
Ivan Grunberger ◽  
Ivan Colon
Keyword(s):  
Prostate Biopsy ◽  
Effective Prophylaxis
Sign in / Sign up

Export Citation Format

Share Document